Table 2.
Predictive value of combined elevated baseline markers for PFS (4 months or 6 months) by treatment arm
| LY2510924 + CE (N = 18) | CE (N = 23) | Total (N = 41) | |
|---|---|---|---|
| Baseline ≥7% CXCR4+ CTCs and ≥6 CTC count | |||
| Kaplan-Meier estimate (mos) | |||
| Mean (SD) | 5.3 (0.4) | 4.9 (0.6) | 5.0 (0.4) |
| Median (95% CI) | 5.5 (3.9, 6.1) | 4.8 (2.9, 6.2) | 4.9 (3.9, 6.1) |
| HR LY2510924 + CE vs CE (95% CI) | 0.94 (0.46, 1.95) | ||
| P-value* | 0.872 | ||
| HR LY2510924 + CE vs CE (95% CI) 4 mos | 0.49 (0.15, 1.59) | ||
| P-value through 4 mos* | 0.223 | ||
| HR LY2510924 + CE vs CE (95% CI) 6 mos | 0.79 (0.34, 1.85) | ||
| P-value through 6 mos* | 0.588 | ||
CE Carboplatin-etoposide, CI Confidence interval, CTCs Circulating tumor cell, HR Hazard ratio, mos Months
*P-value from a log-rank test